← Back to headlines
Eli Lilly Widens Lead in Obesity Drug Race Against Novo Nordisk
Eli Lilly's shares surged after another win against rival Novo Nordisk, further solidifying its lead in the competitive obesity drug market.
23 Feb, 17:49 — 23 Feb, 17:49
ℹOnly 1 source covers this story
